These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1947 related items for PubMed ID: 9749478

  • 21. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA.
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1140-50. PubMed ID: 16198506
    [Abstract] [Full Text] [Related]

  • 22. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
    Stock RG, Stone NN.
    Brachytherapy; 2002 Mar 15; 1(1):2-10. PubMed ID: 15062181
    [Abstract] [Full Text] [Related]

  • 23. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate.
    D'amico AV, Tempany CM, Schultz D, Cormack RA, Hurwitz M, Beard C, Albert M, Kooy H, Jolesz F, Richie JP.
    Urology; 2003 Dec 15; 62(6):1063-7. PubMed ID: 14665356
    [Abstract] [Full Text] [Related]

  • 24. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy.
    D'Amico AV, Renshaw AA, Arsenault L, Schultz D, Richie JP.
    Int J Radiat Oncol Biol Phys; 1999 Nov 01; 45(4):841-6. PubMed ID: 10571187
    [Abstract] [Full Text] [Related]

  • 25. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.
    Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR.
    Eur Urol; 2017 May 01; 71(5):766-773. PubMed ID: 27452951
    [Abstract] [Full Text] [Related]

  • 26. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C, Martínez A, Galalae R, Demanes J, Harsolia A, Schour L, Nuernberg N, Gonzalez J.
    Prostate Cancer Prostatic Dis; 2006 May 01; 9(3):245-53. PubMed ID: 16786040
    [Abstract] [Full Text] [Related]

  • 27. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.
    BJU Int; 2011 Jun 01; 107(11):1748-54. PubMed ID: 20883488
    [Abstract] [Full Text] [Related]

  • 28. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
    Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.
    Ann Intern Med; 2008 Mar 18; 148(6):435-48. PubMed ID: 18252677
    [Abstract] [Full Text] [Related]

  • 29. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA, Katcher J, Levin HS, Klein EA.
    Int J Radiat Oncol Biol Phys; 1997 Mar 15; 37(5):1043-52. PubMed ID: 9169811
    [Abstract] [Full Text] [Related]

  • 30. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.
    Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA.
    Int J Radiat Oncol Biol Phys; 2004 Jan 01; 58(1):25-33. PubMed ID: 14697417
    [Abstract] [Full Text] [Related]

  • 31. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):15-23. PubMed ID: 15337535
    [Abstract] [Full Text] [Related]

  • 32. Prostate brachytherapy: treatment strategies.
    Stone NN, Stock RG.
    J Urol; 1999 Aug 01; 162(2):421-6. PubMed ID: 10411050
    [Abstract] [Full Text] [Related]

  • 33. Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure.
    Stock RG, Berkowitz J, Blacksburg SR, Stone NN.
    BJU Int; 2012 Nov 01; 110(9):1257-61. PubMed ID: 22571680
    [Abstract] [Full Text] [Related]

  • 34. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
    Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR.
    JAMA; 2018 Mar 06; 319(9):896-905. PubMed ID: 29509865
    [Abstract] [Full Text] [Related]

  • 35. Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA <or=10, and clinically localized prostate cancer.
    Cheng GC, Chen MH, Whittington R, Malkowicz SB, Schnall MD, Tomaszewski JE, D'Amico AV.
    Int J Radiat Oncol Biol Phys; 2003 Jan 01; 55(1):64-70. PubMed ID: 12504037
    [Abstract] [Full Text] [Related]

  • 36. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer.
    D'Amico AV, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA.
    Int J Radiat Oncol Biol Phys; 2001 Mar 01; 49(3):679-84. PubMed ID: 11172949
    [Abstract] [Full Text] [Related]

  • 37. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A.
    Lancet Oncol; 2019 Feb 01; 20(2):267-281. PubMed ID: 30579763
    [Abstract] [Full Text] [Related]

  • 38. Optimizing patient selection for prostate monotherapy.
    Lee AK, Schultz D, Renshaw AA, Richie JP, D'Amico AV.
    Int J Radiat Oncol Biol Phys; 2001 Mar 01; 49(3):673-7. PubMed ID: 11172948
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 98.